Skip to main content
Year archive

Cantargia — 2023 filings

All 92 regulatory filings released by Cantargia (CANTA) in 2023, sourced directly from the official regulator.

92 Filings
2023 Period
2023 filings (92)
Filing Released Lang
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-01 Swedish
Nytt antal aktier och röster i Cantargia
Declaration of Voting Results & Voting Rights Announcements
2023-11-30 Swedish
New number of shares and votes in Cantargia
Share Issue/Capital Change
2023-11-30 English
Third party withdraws appeal related to Cantargia patent
Legal Proceedings Report
2023-11-20 English
Tredje part drar tillbaka överklagande relaterat till Cantargias patent
Legal Proceedings Report
2023-11-20 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-10 English
Nomination Committee appointed ahead of 2024 Annual General Meeting
AGM Information
2023-11-03 English
Valberedning utsedd inför årsstämman 2024
Board/Management Information
2023-11-03 Swedish
Cantargia has completed a directed share issue of approximately SEK 59 million
Share Issue/Capital Change
2023-10-30 English
Cantargia har genomfört en riktad nyemission om cirka 59 miljoner kronor
Capital/Financing Update
2023-10-30 Swedish
Cantargia: ESMO 2023 presentation of nadunolimab phase I clinical interim data in triple-negative breast cancer shows promising efficacy and safety
Earnings Release Q1 2023
2023-10-21 English
Cantargia: ESMO 2023-presentation av kliniska fas I-interimsdata för nadunolimab i trippelnegativ bröstcancer visar lovande effekt och säkerhet
Report Publication Announcement
2023-10-21 Swedish
Cantargia: Third party appeals recent EPO decision to maintain granted Cantargia patent
Legal Proceedings Report
2023-10-04 English
Cantargia: Tredje part överklagar beslut av europeiska patentverket (EPO) att upprätthålla godkänt Cantargia-patent
Legal Proceedings Report
2023-10-04 Swedish
Cantargia presents new clinical data further supporting nadunolimab’s antitumor activity and a key role of its target IL1RAP in pancreatic cancer
Regulatory Filings
2023-09-27 English
Cantargia presenterar nya kliniska data som styrker nadunolimabs antitumöraktivitet och visar en nyckelroll för dess måltavla IL1RAP i bukspottkörtelcancer
Regulatory Filings
2023-09-27 Swedish
Cantargia: New preclinical data on nadunolimab potential to enhance anti-tumor effect of immunotherapy presented at CRI-ENCI-AACR
Regulatory Filings
2023-09-20 English
Cantargia: Nya prekliniska data på nadunolimabs potential att förstärka antitumöreffekt av immunterapi presenteras på CRI-ENCI-AACR
Investor Presentation
2023-09-20 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-09-18 English
Cantargia announces new nadunolimab clinical trial in leukemia financed by external US grant
Regulatory Filings
2023-09-18 English
Cantargia meddelar ny klinisk studie med nadunolimab inom leukemi finansierad av externt amerikanskt anslag
Capital/Financing Update
2023-09-18 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-09-06 English
Cantargia: FDA grants Orphan Drug Designation to CAN10 for treatment of systemic sclerosis
Regulatory Filings
2023-09-06 English
Cantargia: FDA beviljar särläkemedelsstatus (Orphan Drug Designation) till CAN10 för behandling av systemisk skleros
Regulatory Filings
2023-09-06 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-09-05 English
Cantargia expands clinical pipeline and starts treatment in second program, CAN10, for autoimmune diseases
Regulatory Filings
2023-09-05 English
Cantargia utökar klinisk pipeline och påbörjar behandling i andra projektet, CAN10, mot autoimmuna sjukdomar
Regulatory Filings
2023-09-05 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-31 English
Director's Dealing 2023
Director's Dealing
2023-08-30 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-29 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-24 English
Interim / Quarterly Report 2023
Interim / Quarterly Report H2 2023
2023-08-22 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H2 2023
2023-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-08-15 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-11 English
Cantargia receives regulatory approval to start phase I clinical trial for CAN10
Regulatory Filings
2023-08-10 English
Cantargia erhåller regulatoriskt godkännande för att starta klinisk fas I-studie med CAN10
Regulatory Filings
2023-08-10 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-08 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-04 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-01 English
Director's Dealing 2023
Director's Dealing
2023-07-28 English
Cantargia reports favorable outcome of patent oppositions in Europe
Legal Proceedings Report
2023-07-05 English
Cantargia meddelar positivt beslut efter oppositioner mot europeiskt patent
Regulatory Filings
2023-07-05 Swedish
Cantargia announces updates to the management team
Board/Management Information
2023-06-01 English
Cantargia meddelar om förändringar i bolagets ledningsgrupp
Board/Management Information
2023-06-01 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-05-31 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-05-29 English
Cantargia presenterar lovande effektdata för nadunolimab i icke-småcellig lungcancer på ASCO 2023, med två kompletta responser
Regulatory Filings
2023-05-25 Swedish
Cantargia to present promising nadunolimab efficacy in non-small cell lung cancer at ASCO 2023, including two complete responses
Earnings Release FY 2023
2023-05-25 English
Annual General Meeting in Cantargia AB (publ)
AGM Information
2023-05-23 English
Årsstämma i Cantargia AB (publ)
AGM Information
2023-05-23 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-23 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-23 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-05-22 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-05-19 English
Cantargia intensifies development of nadunolimab in pancreatic cancer with new controlled phase IIb clinical trial following strong phase IIa efficacy results
Regulatory Filings
2023-05-15 English
Cantargia intensifierar utvecklingen av nadunolimab i bukspottkörtelcancer genom ny kontrollerad fas IIb-klinisk studie efter starka fas IIa-effektdata
Regulatory Filings
2023-05-15 Swedish
Annual Report 2022
Annual Report FY 2022
2023-04-27 Swedish
Annual Report 2022
Annual Report FY 2022
2023-04-27 English
Notice of annual general meeting in Cantargia AB (publ)
AGM Information
2023-04-24 English
Kallelse till årsstämma i Cantargia AB (publ)
AGM Information
2023-04-24 Swedish
Cantargia reports favorable safety of new nadunolimab combination therapy and completes enrollment in non-small cell lung cancer trial
Regulatory Filings
2023-04-21 English
Cantargia meddelar god säkerhet av ny kombinationsbehandling med nadunolimab och avslutar rekrytering till studie i icke-småcellig lungcancer
Regulatory Filings
2023-04-21 Swedish
Cantargia has submitted a phase I clinical trial application for its second project, CAN10
Regulatory Filings
2023-04-20 English
Cantargia har lämnat in ansökan om klinisk fas I-studie för dess andra projekt, CAN10
Regulatory Filings
2023-04-20 Swedish
Cantargia presents anti-metastatic effects of nadunolimab in cancer models at AACR 2023
Legal Proceedings Report
2023-04-19 English
Cantargia presenterar anti-metastaserande effekter av nadunolimab i cancermodeller på AACR 2023
Regulatory Filings
2023-04-19 Swedish
Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer
Regulatory Filings
2023-04-17 English
Cantargia presenterar nya kliniska data på AACR 2023 som kraftfullt stöder utvecklingen av nadunolimab i bukspottkörtelcancer
Earnings Release FY 2023
2023-04-17 Swedish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-03-28 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-03-23 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-03-20 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-03-17 English
Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer
Regulatory Filings
2023-03-14 English
Cantargia presenterar positiva resultat för nadunolimab på AACR 2023 med nya kliniska data i bukspottkörtelcancer
Earnings Release FY 2023
2023-03-14 Swedish
Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial
Regulatory Filings
2023-03-14 English
Cantargia behandlar första patienten med trippelnegativ bröstcancer i randomiserad fas II-del i TRIFOUR-studien
Regulatory Filings
2023-03-14 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report FY 2022
2023-02-23 Swedish
Annual Report 2022
Annual Report FY 2022
2023-02-23 English
Cantargia startar randomiserad del i TRIFOUR-studien baserat på lovande tidig säkerhet och effekt med nadunolimab i trippelnegativ bröstcancer
Regulatory Filings
2023-02-23 Swedish
Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer
Earnings Release Q1 2023
2023-02-23 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-02-07 English
Cantargia meddelar rekrytering av Patrik Renblad som Chief Financial Officer
Board/Management Information
2023-02-01 Swedish
Cantargia announces appointment of Patrik Renblad as Chief Financial Officer
Board/Management Information
2023-02-01 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-31 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-30 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-17 English
Director's Dealing 2023
Director's Dealing
2023-01-16 English
Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application
Regulatory Filings
2023-01-13 English
Cantargia slutför framgångsrikt toxicitetsstudie för CAN10-antikroppen inför ansökan om klinisk fas I-studie
Legal Proceedings Report
2023-01-13 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-13 English